内科

目的探讨注射用尿促性素联合来曲唑治疗排卵障碍性不孕患者的临床效果。方法选取2017年1月至2019年12月我院收治的排卵障碍性不孕患者94例为研究对象，按照患者就诊顺序分为观察组和对照组，每组47例。对照组患者给予注射用尿促性素及克罗米芬治疗，观察组患者给予注射用尿促性素及来曲唑治疗。两组患者均治疗6个月经周期。比较两组患者治疗后的成熟卵泡数量、排卵率及妊娠率；比较两组患者治疗前后的子宫内膜厚度、主卵泡直径、血清激素水平；比较两组患者治疗期间及治疗结束45 d内的不良事件发生情况。结果治疗6个月经周期后，观察组患者的成熟卵泡数量、子宫内膜厚度、主卵泡直径显著多（大）于对照组，观察组患者的排卵率、妊娠率显著高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的雌二醇（E2）、卵泡刺激素（FSH）、促黄体生成素（LH）水平比较差异无统计学意义（P＞0.05）；治疗6个月经周期后，两组患者的E2、FSH、LH水平均显著升高，观察组患者的水平显著高于对照组，差异有统计学意义（P＜0.05）。治疗期间及治疗结束45 d内，观察组患者的不良事件发生率（4.26%）显著低于对照组（19.15%），差异有统计学意义（P＜0.05）。结论注射用尿促性素联合来曲唑治疗排卵障碍性不孕患者临床疗效显著，能显著提高患者的排卵率和妊娠率。

ObjectiveTo explore the clinical effect of menotrophin for injection combined with letrozole in the treatment of patients with ovulatory obstacle infertility. MethodsA total of 94 patients with ovulatory obstacle infertility admitted to our hospital from January 2017 to December 2019 were selected as the research objects, and they were randomly divided into observation group and control group, with 47 cases in each group. The control group was treated with menotrophin for injection and clomiphene, and the observation group was treated with menotrophin for injection and letrozole. Both groups were treated for 6 menstrual cycles. The number of mature follicles, ovulation rate and pregnancy rate of the two groups after treatment were compared. The pre- and post-treatment endometrial thickness, main follicle diameter, and serum hormone level were compared between the two groups. The occurrence of adverse events during the treatment and within 45 days after treatment was compared between the two groups. ResultsAfter 6 menstrual cycles of treatment, the patients in the observation group obtained a greater (larger) number of mature follicles, endometrial thickness, and main follicle diameter, and higher ovulation rate and pregnancy rate as compared with the control group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in the levels of estradiol (E2), follicle stimulating hormone (FSH), and luteinizing hormone (LH) between the two groups (P＞0.05). After 6 menstrual cycles of treatment, the levels mentioned above increased in both groups, and the levels of the observation group were significantly higher than those of the control group, with statistically significant differences (P＜0.05). During the treatment and within 45 days after treatment, the incidence of adverse events in the observation group (4.26%) was significantly lower than that in the control group (19.15%), with a statistically significant difference (P＜0.05). ConclusionMenotrophin for injection combined with letrozole in the treatment of patients with ovulatory obstacle infertility has a significant clinical efficacy, and can significantly improve the ovulation rate and pregnancy rate in patients.